PER

0.00%

10.5¢ percheron therapeutics limited

Correction: … were disgruntled 8 months after the CR, not...

First 2723 Last

Share
Profile

Follow
BoomCrashOffera

720 Posts.

210

07/09/23

11:10

Post #: 69766753
Share

Originally posted by BoomCrashOffera: ↑

Hi Itsa,

I’d like to respond to your attack on Sam’s “writing” on his behalf in a (hopefully) non-inflammatory way and hopefully cut short the usual to-and-fro argument dynamic where you cast aspersions (often from misinterpretation imo) and Sam feels compelled to defend himself. I suspect he is caught between posting a response and not posting one for the sake of peace.

Albeit that Sam reposted a post from over 6 months ago to make the point that he felt then (and now) that the combo development was important, you have attacked him on an ancillary point where I believe you have misunderstood him.

Sam never said in the post (and has never claimed) that the CR at 24c was to fund the WHOLE original, EMA approved, pivotal trial. He was making the point that the intended use of funds from the CR Nov 2021 (that we all here know and that was clearly laid out in the CR presentation) was meant (and sold to Platinum) to GO TOWARDS FUNDING A PIVOTAL TRIAL as laid out then.

Everyone here knows (and he wouldn’t be so stupid to claim otherwise) that the structure of that trial funding and CR relied on 48c option exercise at futility to complete the other $37 mill (half of trial funding). A CR which later became flawed based on the initial funding entitlement shortfall (making it now $50 mill required), the subsequent sinking share price, and the realisation that $37 mill in future trial funding was resting on a “stop” or “keep going” announcement at futility with no revealing of unblinded data, to make the SP trade above 48c.

It would be easy to connect dots (and this is my opinion) that Platinum were also disgruntled 8 months after the trial when they chose to sell over a million shares around 12c after ANP came out of a trading halt on a Long Covid announcement. Platinum announced that they were now under the 5% threshold for reporting trades (and therefore able to sell further without having to report). Instos (imo) who hold majority shareholder, reportable, cornerstone investment stakes don’t often sell at 50% of their recent placement entry price if they are still happily in it for the long term. Anyway that’s just my opinion.

It wasn’t long after that we had a trial redesign to a P2b that was at the time, no guarantee (and still isn’t despite reassurances) of not requiring a further trial before regulatory approval.

Anyway, hope that may explain a misunderstanding that a lot of us here (I suspect) have seen.

Expand

Correction:

… were disgruntled 8 months after the CR, not “trial”.

ANP Price at posting: 6.3¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 812 more messages in this thread...

First 2723 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.5¢		Change 0.000(0.00%)		Mkt cap ! $94.66M

Open	High	Low	Value	Volume
10.5¢	10.5¢	9.8¢	$58.09K	574.8K

Buyers (Bids)

No.	Vol.	Price($)
1	38503	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	194063	5

View Market Depth

No.	Vol.	Price($)
1	100000	0.099
2	108491	0.098
1	30927	0.097
1	10004	0.096
3	162157	0.095

Price($)	Vol.	No.
0.105	194063	5
0.110	254663	3
0.115	1334300	6
0.120	381142	9
0.125	110429	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PER (ASX) Chart

Correction: … were disgruntled 8 months after the CR, not...

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Correction: … were disgruntled 8 months after the CR, not...

Top Stories

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News